Katarina LeBlanc

Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT®) Mesenchymal Stromal Cell committee position statement on nomenclature

Sowmya Viswanathan, Yufang Shi, Jacques Galipeau et al. · Cytotherapy · 2019 · 777 citations

Regenerative Medicine, Cell Therapy, Developmental Biology +12

Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms

Ida Rasmusson, Olle Ringdén, Björn Sundberg et al. · Experimental Cell Research · 2005 · 495 citations

Regenerative Medicine, Mesenchymal Stem Cells, Different Mechanisms +10

International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials

Jacques Galipeau, Mauro Krampera, John Barrett et al. · Cytotherapy · 2015 · 491 citations · Full text

Cell Therapy, International Society, Medicine +10

Treatment with mesenchymal stromal cells is a risk factor for pneumonia‐related death after allogeneic hematopoietic stem cell transplantation

Ulrica Forslöw, Ola Blennow, Katarina LeBlanc et al. · European Journal Of Haematology · 2012 · 82 citations

Targeted monitoring of patients at high risk of post‐transplant lymphoproliferative disease by quantitative Epstein–Barr virus polymerase chain reaction

Hamdy Omar, H Hägglund, Åsa Gustafsson‐Jernberg et al. · Transplant Infectious Disease · 2009 · 76 citations